SGLT2 inhibitor use also correlated with lower rates of psychiatric ED visits ...

A 112,000-patient study links SGLT2 inhibitors to lower dementia risk in people with psychiatric disorders. Read what it could mean.

The SGLT2 inhibitors market is experiencing robust growth, driven by the rising prevalence of type 2 diabetes and chronic kidney disease worldwide. Additionally, the expected launch of emerging SGLT2 ...

CHICAGO — For older patients at high risk for a heart failure event who are scheduled for transcatheter aortic valve implantation (TAVI), dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) ...

A diabetes drug called dapagliflozin may help prevent heart failure in people with genetic variants linked to cardiomyopathy, ...

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there have been questions as to whether it is safe to use these drugs in patients ...

Abnormal creatinine in CKD can justify SGLT2 inhibitor initiation irrespective of diabetes status, given robust renal and ...

Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide a beneficial choice of treatment for patients with type 2 diabetes (diabetes mellitus/T2DM). It can be used as an alternative for those who ...

Retrospective single-center review of 80 HFrEF patients added SGLT2 inhibitors on stable guideline-directed therapy, with ...

Using a GLP-1 receptor agonist in combination with an SGLT2 inhibitor may provide additive cardiovascular and renal benefits ...